Kenfen Li, Yanping Zhang, Yunfeng Wang, Xin Guo, Xianhui Dai, L. Song
{"title":"lncRNA前列腺雄激素调节转录物1(PART-1)通过调节miR-204-3p/IGFBP-2途径促进非小细胞肺癌癌症进展","authors":"Kenfen Li, Yanping Zhang, Yunfeng Wang, Xin Guo, Xianhui Dai, L. Song","doi":"10.1515/labmed-2022-0082","DOIUrl":null,"url":null,"abstract":"Abstract Objectives Lung cancer is a common malignant tumour of the lung and the leading cause of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for 80–85% of lung cancers, and 40% of NSCLCs have spread beyond the lungs by the time they are diagnosed. The long noncoding RNA (lncRNA) prostate androgen-regulated transcript 1 (PART-1) has been reported to promote the development of several cancers. Methods In the current study, we investigated the role of PART-1 in the proliferation, invasion, and migration of NSCLC. Results The expression levels of the PART-1 gene were higher in NSCLC cell lines, including A549, H1229, H1650, H1975, and PC9, than in human bronchial epithelia (HBE) cell lines. Knocking down PART-1 inhibited the proliferation, invasion, and migration of A549 cells and decreased tumour proliferation in nude mice. We confirmed that PART-1 targeted miR-204-3p directly and that miR-204-3p targeted insulin-like growth factor binding protein 2 (IGFBP-2) directly. Furthermore, we discovered that PART-1 impacts NSCLC progression by regulating the miR-204-3p-targeted IGFBP-2 pathway. Conclusions The lncRNA PART-1 might be a target for treating NSCLC and an early marker in the diagnosis of early lung cancer.","PeriodicalId":55986,"journal":{"name":"Journal of Laboratory Medicine","volume":"47 1","pages":"31 - 40"},"PeriodicalIF":1.1000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The lncRNA prostate androgen-regulated transcript 1 (PART-1) promotes non-small cell lung cancer progression by regulating the miR-204-3p/IGFBP-2 pathway\",\"authors\":\"Kenfen Li, Yanping Zhang, Yunfeng Wang, Xin Guo, Xianhui Dai, L. Song\",\"doi\":\"10.1515/labmed-2022-0082\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Objectives Lung cancer is a common malignant tumour of the lung and the leading cause of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for 80–85% of lung cancers, and 40% of NSCLCs have spread beyond the lungs by the time they are diagnosed. The long noncoding RNA (lncRNA) prostate androgen-regulated transcript 1 (PART-1) has been reported to promote the development of several cancers. Methods In the current study, we investigated the role of PART-1 in the proliferation, invasion, and migration of NSCLC. Results The expression levels of the PART-1 gene were higher in NSCLC cell lines, including A549, H1229, H1650, H1975, and PC9, than in human bronchial epithelia (HBE) cell lines. Knocking down PART-1 inhibited the proliferation, invasion, and migration of A549 cells and decreased tumour proliferation in nude mice. We confirmed that PART-1 targeted miR-204-3p directly and that miR-204-3p targeted insulin-like growth factor binding protein 2 (IGFBP-2) directly. Furthermore, we discovered that PART-1 impacts NSCLC progression by regulating the miR-204-3p-targeted IGFBP-2 pathway. Conclusions The lncRNA PART-1 might be a target for treating NSCLC and an early marker in the diagnosis of early lung cancer.\",\"PeriodicalId\":55986,\"journal\":{\"name\":\"Journal of Laboratory Medicine\",\"volume\":\"47 1\",\"pages\":\"31 - 40\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Laboratory Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1515/labmed-2022-0082\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Laboratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/labmed-2022-0082","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
The lncRNA prostate androgen-regulated transcript 1 (PART-1) promotes non-small cell lung cancer progression by regulating the miR-204-3p/IGFBP-2 pathway
Abstract Objectives Lung cancer is a common malignant tumour of the lung and the leading cause of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for 80–85% of lung cancers, and 40% of NSCLCs have spread beyond the lungs by the time they are diagnosed. The long noncoding RNA (lncRNA) prostate androgen-regulated transcript 1 (PART-1) has been reported to promote the development of several cancers. Methods In the current study, we investigated the role of PART-1 in the proliferation, invasion, and migration of NSCLC. Results The expression levels of the PART-1 gene were higher in NSCLC cell lines, including A549, H1229, H1650, H1975, and PC9, than in human bronchial epithelia (HBE) cell lines. Knocking down PART-1 inhibited the proliferation, invasion, and migration of A549 cells and decreased tumour proliferation in nude mice. We confirmed that PART-1 targeted miR-204-3p directly and that miR-204-3p targeted insulin-like growth factor binding protein 2 (IGFBP-2) directly. Furthermore, we discovered that PART-1 impacts NSCLC progression by regulating the miR-204-3p-targeted IGFBP-2 pathway. Conclusions The lncRNA PART-1 might be a target for treating NSCLC and an early marker in the diagnosis of early lung cancer.
期刊介绍:
The Journal of Laboratory Medicine (JLM) is a bi-monthly published journal that reports on the latest developments in laboratory medicine. Particular focus is placed on the diagnostic aspects of the clinical laboratory, although technical, regulatory, and educational topics are equally covered. The Journal specializes in the publication of high-standard, competent and timely review articles on clinical, methodological and pathogenic aspects of modern laboratory diagnostics. These reviews are critically reviewed by expert reviewers and JLM’s Associate Editors who are specialists in the various subdisciplines of laboratory medicine. In addition, JLM publishes original research articles, case reports, point/counterpoint articles and letters to the editor, all of which are peer reviewed by at least two experts in the field.